患者与胃肠病学家对克罗恩病降阶梯治疗的看法
Perspectives From Patients and Gastroenterologists on De-escalating Therapy for Crohn's Disease.
PubMed 文献 · Clin Gastroenterol Hepatol · 2019-12-27
本文探讨克罗恩病患者与胃肠病学家对降阶梯治疗(停用抗TNF药物和/或硫唑嘌呤/巯嘌呤)的看法。联合治疗在早期使用成功率最高,但因费用和长期副作用担忧,患者和提供者常询问停药问题。
要点
- 抗TNF联合硫唑嘌呤/巯嘌呤在早期使用成功率最高。
- 药物费用高和长期副作用担忧是降阶梯治疗的主要驱动因素。
- 患者和提供者常询问停用联合治疗中的一种或两种药物。
核心结论
- 克罗恩病联合治疗早期成功率最高,但费用和副作用担忧促使患者和医生考虑降阶梯治疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
In Crohn's disease, combination therapy with anti-tumor necrosis factor (anti-TNF) agents and azathioprine/mercaptopurine has been shown to be superior to monotherapy with one of these treatments alone.1 This combination has its best success rate when used early in the course of treatment.2 However, because of the significant cost of these drugs and concerns over long-term side effects,3,4 many patients and providers often ask about stopping one or both of these medications.
来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。
引用
- Siegel CA, Thompson KD, Walls D, et al. Perspectives From Patients and Gastroenterologists on De-escalating Therapy for Crohn's Disease. Clin Gastroenterol Hepatol. 2019. PMID: 31887442. doi:10.1016/j.cgh.2019.11.062
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。